All-oral direct-acting Antiviral Therapy Against Hepatitis C Virus (HCV) in Human Immunodeficiency Virus/HCV– Coinfected Subjects in Real-World Practice: Madrid Coinfection Registry Findings
Author
Berenguer, Juan; Gil-Martin, Ángela; Jarrin, Inmaculada; Moreno, Ana; Dominguez, Lourdes; Montes, Marisa; Aldámiz-Echevarría, Teresa; Téllez, María J.; Santos Gil, Ignacio de los; Benítez, Laura; Sanz, José; Ryan, Pablo; Gaspar, Gabriel; Álvarez, Beatriz; Losa, Juan E.; Torres-Perea, Rafael; Barros, Carlos; San Martín, Juan V.; Arponen, Sari; Guzmán, María T. de; Monsalvo, Raquel; Vegas, Ana; García-Benayas, María T.; Serrano, Regino; Gotuzzo, Luis; Menéndez, María Antonia; Belda, Luis M.; Malmierca, Eduardo; Calvo, María J.; Cruz-Martos, Encarnación; González García, Juan JuliánEntity
UAM. Departamento de Medicina; UAM. Departamento de Anatomía, Histología y NeurocienciaPublisher
American Association for the Study of Liver Diseases (AASLD)Date
2018Citation
10.1002/hep.29814
Hepatology 68.1 (2018): 32-47
ISSN
0270-9139 (print); 1527-3350 (online)DOI
10.1002/hep.29814Editor's Version
https://doi.org/10.1002/hep.29814Subjects
Therapy; Hepatitis C Virus (HCV); HCV; Coinfected patients; HCV RNA; MedicinaAbstract
We evaluated treatment outcomes in a prospective registry of human immunodeficiency virus/hepatitis C virus (HCV)–coinfected
patients treated with interferon-free direct-acting antiviral agent–based therapy in hospitals from the region of Madrid between
November 2014 and August 2016.We assessed sustained viral response at 12 weeks after completion of treatment and used multivariable
logistic regression to identify predictors of treatment failure.We evaluated 2,369 patients, of whom 59.5% did not have cirrhosis,
33.9% had compensated cirrhosis, and 6.6% had decompensated cirrhosis. The predominant HCV genotypes were 1a
(40.9%), 4 (22.4%), 1b (15.1%), and 3 (15.0%). Treatment regimens included sofosbuvir (SOF)/ledipasvir (61.9%), SOF plus
daclatasvir (14.6%), dasabuvir plus ombitasvir/paritaprevir/ritonavir (13.2%), and other regimens (10.3%). Ribavirin was used in
30.6% of patients. Less than 1% of patients discontinued therapy owing to adverse events. The frequency of sustained viral response
by intention-to-treat analysis was 92.0% (95% confidence interval, 90.9%-93.1%) overall, 93.8% (92.4%-95.0%) for no cirrhosis,
91.0% (88.8%-92.9%) for compensated cirrhosis, and 80.8% (73.7%-86.6%) for decompensated cirrhosis. The factors associated
with treatment failure were male sex (adjusted odds ratio, 1.75; 95% confidence interval, 1.14-2.69), Centers for Diseases Control
and Prevention category C (adjusted odds ratio, 1.65; 95% confidence interval, 1.12-2.41), a baseline cluster of differentiation 4–
positive (CD41) T-cell count <200/mm3 (adjusted odds ratio, 2.30; 95% confidence interval, 1.35-3.92), an HCV RNA load
800,000 IU/mL (adjusted odds ratio, 1.63; 95% confidence interval, 1.14-2.36), compensated cirrhosis (adjusted odds ratio, 1.35;
95% confidence interval, 0.96-1.89), decompensated cirrhosis (adjusted odds ratio, 2.92; 95% confidence interval, 1.76-4.87), and
the use of SOF plus simeprevir, SOF plus ribavirin, and simeprevir plus daclatasvir. Conclusion: In this large real-world study,
direct-acting antiviral agent–based therapy was safe and highly effective in coinfected patients; predictors of failure included gender,
human immunodeficiency virus–related immunosuppression, HCV RNA load, severity of liver disease, and the use of suboptimal
direct-acting antiviral agent–based regimens.
Files in this item
Google Scholar:Berenguer, Juan
-
Gil-Martin, Ángela
-
Jarrin, Inmaculada
-
Moreno, Ana
-
Dominguez, Lourdes
-
Montes, Marisa
-
Aldámiz-Echevarría, Teresa
-
Téllez, María J.
-
Santos Gil, Ignacio de los
-
Benítez, Laura
-
Sanz, José
-
Ryan, Pablo
-
Gaspar, Gabriel
-
Álvarez, Beatriz
-
Losa, Juan E.
-
Torres-Perea, Rafael
-
Barros, Carlos
-
San Martín, Juan V.
-
Arponen, Sari
-
Guzmán, María T. de
-
Monsalvo, Raquel
-
Vegas, Ana
-
García-Benayas, María T.
-
Serrano, Regino
-
Gotuzzo, Luis
-
Menéndez, María Antonia
-
Belda, Luis M.
-
Malmierca, Eduardo
-
Calvo, María J.
-
Cruz-Martos, Encarnación
-
González García, Juan Julián
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype
Berenguer, Juan; Calleja Panero, José Luis; Montes, María Luisa; Gil, Ángela; Moreno, Ana; Bañares, Rafael; Aldámiz-Echevarría, Teresa; Albillos, Agustín; Téllez, María Jesús; Olveira, Antonio; Domínguez, Lourdes; Fernández, Inmaculada; García-Samaniego, Javier; Polo, Benjamín A.; Álvarez, Beatriz; Ryan, Pablo; Barrio, José; Devesa, María J.; Benítez, Laura; Santos Gil, Ignacio de los; Buey, Luisa García; Sanz, José; Poves, Elvira; Losa, Juan E.; Fernández-Rodríguez, Conrado; Jarrín, Inmaculada; Calvo, María J.; González García, Juan Julián
2019-05-01